Bausch Pulls Xifaxan From Medicaid/340B As Medicare Negotiated Price Looms

 
• By Cathy Kelly
  
Xifaxan sales in Medicaid and 340B may have become a liability. (Shutterstock)
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Medicaid

More from Government Payers